HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

DEA Takes Comments On Kratom, But Keeps Eye On Scheduling

This article was originally published in The Rose Sheet

Executive Summary

DEA will accept comments through Dec. 1 on its proposal to move the active materials in kratom into Schedule I under CSA to avoid an imminent hazard to public safety.

You may also be interested in...



Another Notice For Comments On Kratom: Cue Second Wave Of Support For Botanical In US?

FDA states in Federal Register notice that WHO has requested information on whether kratom – mitragynine, 7-hydroxymitragynine – should be added to the United Nations’ schedule of controlled substances.

Schedule Kratom? Promoted By Former US FDA Commissioner, Opposed By Former Top HHS Official

Former commissioner Scott Gottlieb and former HHS health chief Brett Giroir make clear they haven’t changed their minds in Twitter posts following FDA kratom seizure announcement.

US HHS Pulled Recommendation To Make Kratom A Controlled Substance, But Kept Mum On Change

HHS released to industry proponents Reps. Mark Pocan and Morgan Griffith the letter it submitted in 2018 notifying DEA that it was rescinding recommendation it made in 2017 to list kratom active ingredients mitragynine and 7-hydroxymitragynine under Schedule I of the CSA.

Related Content

Topics

UsernamePublicRestriction

Register

RS108623

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel